Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort

[EN] Objective: Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed t...

Descripción completa

Detalles Bibliográficos
Autores: Segura, Alex G., Martínez Pinteño, Albert, Gassó, Patricia, Rodríguez, Natalia, Cuesta, Manuel J., González Peñas, Javier, García Rizo, Clemente, Lobo, Antonio, González Pinto Arrillaga, Ana María, García Alcón, Alicia, Roldán, Alexandra, Vieta, Eduard, Castro Fornieles, Josefina, Mané, Anna, Saiz, Jerónimo, Bernardo, Miguel, Mas, Sergi, PEPs Group
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/57408
Acceso en línea:http://hdl.handle.net/10810/57408
Access Level:acceso abierto
Palabra clave:psychotic disorders
metabolic syndrome
polygenic risk score
id ES_0bbb4e730fc500be9d0913818f7e3dbc
oai_identifier_str oai:addi.ehu.eus:10810/57408
network_acronym_str ES
network_name_str España
repository_id_str
spelling Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohortSegura, Alex G.Martínez Pinteño, AlbertGassó, PatriciaRodríguez, NataliaCuesta, Manuel J.González Peñas, JavierGarcía Rizo, ClementeLobo, AntonioGonzález Pinto Arrillaga, Ana MaríaGarcía Alcón, AliciaRoldán, AlexandraVieta, EduardCastro Fornieles, JosefinaMané, AnnaSaiz, JerónimoBernardo, MiguelMas, SergiPEPs Grouppsychotic disordersmetabolic syndromepolygenic risk score[EN] Objective: Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: Of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses.Results: No major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR <= 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance).Conclusion: Our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.Elsevier202220222022info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10810/57408reponame:Addi. Archivo Digital para la Docencia y la Investigacióninstname:Universidad del País VascoIngléshttps://www.sciencedirect.com/science/article/pii/S0920996422001980?via%3Dihubinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/3.0/es/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Atribución-NoComercial-SinDerivadas 3.0 Españaoai:addi.ehu.eus:10810/574082026-06-18T09:23:17Z
dc.title.none.fl_str_mv Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
title Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
spellingShingle Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
Segura, Alex G.
psychotic disorders
metabolic syndrome
polygenic risk score
title_short Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
title_full Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
title_fullStr Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
title_full_unstemmed Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
title_sort Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort
dc.creator.none.fl_str_mv Segura, Alex G.
Martínez Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Cuesta, Manuel J.
González Peñas, Javier
García Rizo, Clemente
Lobo, Antonio
González Pinto Arrillaga, Ana María
García Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro Fornieles, Josefina
Mané, Anna
Saiz, Jerónimo
Bernardo, Miguel
Mas, Sergi
PEPs Group
author Segura, Alex G.
author_facet Segura, Alex G.
Martínez Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Cuesta, Manuel J.
González Peñas, Javier
García Rizo, Clemente
Lobo, Antonio
González Pinto Arrillaga, Ana María
García Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro Fornieles, Josefina
Mané, Anna
Saiz, Jerónimo
Bernardo, Miguel
Mas, Sergi
PEPs Group
author_role author
author2 Martínez Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Cuesta, Manuel J.
González Peñas, Javier
García Rizo, Clemente
Lobo, Antonio
González Pinto Arrillaga, Ana María
García Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro Fornieles, Josefina
Mané, Anna
Saiz, Jerónimo
Bernardo, Miguel
Mas, Sergi
PEPs Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv psychotic disorders
metabolic syndrome
polygenic risk score
topic psychotic disorders
metabolic syndrome
polygenic risk score
description [EN] Objective: Metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: Of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses.Results: No major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR <= 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance).Conclusion: Our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10810/57408
url http://hdl.handle.net/10810/57408
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0920996422001980?via%3Dihub
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
Atribución-NoComercial-SinDerivadas 3.0 España
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/3.0/es/
Atribución-NoComercial-SinDerivadas 3.0 España
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Addi. Archivo Digital para la Docencia y la Investigación
instname:Universidad del País Vasco
instname_str Universidad del País Vasco
reponame_str Addi. Archivo Digital para la Docencia y la Investigación
collection Addi. Archivo Digital para la Docencia y la Investigación
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403244451594240
score 15,300719

Similares en LA Referencia